Table 3.

Meta-analysis of the efficacy of MSC in the therapy of patients with lupus nephritis (self-control).

Indicators	Time point	Studies	Q test	Model	WMD	P
		Number	P value	Selected	(95% CI)
Proteinuria	1 month	2	0.83	Fixed	-0.69 (-1.02, -0.36)	<0.0001
	2 months	2	0.46	Fixed	-1.51 (-2.40, -0.63)	0.0008
	3 months	3	<0.00001	Random	-1.25(-2.00, -0.51)	0.001
	4 months	1	—	Fixed	-2.04 (-3.00, -1.08)	<0.0001
	6 months	5	0.06	Random	-1.56 (-2.14, -0.98)	<0.00001
	12 months	2	<0.00001	Random	-1.82 (-2.96, -0.67)	0.002
Scr	1 month	3	0.32	Fixed	-7.28 (-21.97, 7.41)	0.33
	2 months	2	0.0006	Random	-59.18 (-166.92, 48.56)	0.28
	3 months	3	<0.00001	Random	-75.13 (-187.01, 36.76)	0.19
	4 months	1	—	Fixed	-10.25 (-25.34, 4.84)	0.18
	6 months	2	0.72	Fixed	-14.08 (-28.09, -0.07)	0.05
	12 months	2	0.88	Fixed	-30.00 (-38.89, -21.10)	<0.00001
BUN	1 month	1	—	Fixed	-610.6 (-835.84, -385.36)	<0.00001
	2 months	1	—	Fixed	-758.4 (-960.42, -556.38)	<0.00001
	3 months	3	<0.00001	Random	-21.31 (-46.58, 3.97)	0.10
	12 months	2	0.05	Random	-4.14 (-7.89, -0.39)	0.03
C3	1 month	2	0.69	Fixed	0.15 (0.06, 0.24)	0.0006
	2 months	2	0.70	Fixed	0.25 (0.17, 0.33)	<0.00001
	3 months	3	<0.00001	Random	0.37 (-0.01, 0.76)	0.06
	4 months	1	—	Fixed	0.33 (0.13, 0.53)	0.001
	6 months	3	0.009	Random	0.23 (0.06, 0.39)	0.006
	12 months	1	—	Fixed	0.96 (0.88, 1.04)	<0.00001
C4	1 month	2	0.51	Fixed	0.02 (-0.01, 0.04)	0.25
	2 months	2	1.00	Fixed	0.05 (0.02, 0.08)	0.0001
	3 months	2	0.04	Random	0.11 (0.07, 0.15)	<0.00001
	4 months	1	—	Fixed	0.07 (0.04, 0.10)	<0.0001
	6 months	2	0.009	Random	0.06 (-0.02, 0.14)	0.15
	12 months	1	—	Fixed	0.24 (0.22, 0.26)	<0.00001
SLEDAI	1 month	5	0.02	Random	-3.83 (-5.42, -2.23)	<0.00001
	2 months	2	0.15	Fixed	-4.38 (-6.24, -2.51)	<0.00001
	3 months	4	0.88	Fixed	-5.45 (-6.19, -4.72)	<0.00001
	4 months	1	—	Fixed	-6.35 (-8.27, -4.43)	<0.00001
	6 months	6	0.87	Fixed	-7.20 (-7.99, -6.42)	<0.00001
	12 months	3	0.51	Fixed	-8.06 (-8.79, -7.33)	<0.00001